Viking Therapeutics, Inc. Operating Expenses
Viking Therapeutics, Inc. (VKTX) reported Operating Expenses of $132.60 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-07-29
- Viking Therapeutics, Inc. operating expenses for the quarter ending 2026-06-30 was $132.60M, a 77.81% increase year-over-year.
- Viking Therapeutics, Inc. operating expenses for the quarter ending 2026-03-31 was $164.13M, a 195.89% increase year-over-year.
- Viking Therapeutics, Inc. operating expenses for the quarter ending 2025-12-31 was $164.74M, a 256.28% increase year-over-year.
- Viking Therapeutics, Inc. operating expenses for the quarter ending 2025-09-30 was $98.56M, a 169.62% increase year-over-year.
- Viking Therapeutics, Inc. operating expenses for fiscal 2025 was $393.34M, a 160.63% increase from fiscal 2024.
- Viking Therapeutics, Inc. operating expenses for fiscal 2024 was $150.92M, a 49.68% increase from fiscal 2023.
- Viking Therapeutics, Inc. operating expenses for fiscal 2023 was $100.83M, a 43.31% increase from fiscal 2022.
- Viking Therapeutics, Inc. operating expenses for fiscal 2022 was $70.36M, a 26.35% increase from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 3 month as first filed | Operating Expenses 6 month | Operating Expenses 6 month as first filed | Operating Expenses 9 month | Operating Expenses 9 month as first filed | Operating Expenses 12 month | Operating Expenses 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $132.60M 10-Q · filed 2026-07-29 | $296.72M 10-Q · filed 2026-07-29 | $461.46M derived: sum of 3 quarters · filed 2026-07-29 | $560.02M derived: sum of 4 quarters · filed 2026-07-29 | ||||
| 2026-03-31 | $164.13M 10-Q · filed 2026-04-30 | $328.86M derived: sum of 2 quarters · filed 2026-04-30 | $427.42M derived: sum of 3 quarters · filed 2026-04-30 | $502.00M derived: sum of 4 quarters · filed 2026-07-29 | ||||
| 2025-12-31 | $164.74M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $263.30M derived: sum of 2 quarters · filed 2026-02-11 | $337.87M derived: sum of 3 quarters · filed 2026-07-29 | $393.34M 10-K · filed 2026-02-11 | ||||
| 2025-09-30 | $98.56M 10-Q · filed 2025-10-23 | $173.13M derived: sum of 2 quarters · filed 2026-07-29 | $228.60M 10-Q · filed 2025-10-23 | $274.84M derived: sum of 4 quarters · filed 2026-07-29 | ||||
| 2025-06-30 | $74.57M 10-Q · filed 2026-07-29 | $130.04M 10-Q · filed 2026-07-29 | $176.28M derived: sum of 3 quarters · filed 2026-07-29 | $212.84M derived: sum of 4 quarters · filed 2026-07-29 | ||||
| 2025-03-31 | $55.47M 10-Q · filed 2026-04-30 | $101.71M derived: sum of 2 quarters · filed 2026-04-30 | $138.26M derived: sum of 3 quarters · filed 2026-04-30 | $172.32M derived: sum of 4 quarters · filed 2026-04-30 | ||||
| 2024-12-31 | $46.24M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $82.79M derived: sum of 2 quarters · filed 2026-02-11 | $116.85M derived: sum of 3 quarters · filed 2026-02-11 | $150.92M 10-K · filed 2026-02-11 | ||||
| 2024-09-30 | $36.56M 10-Q · filed 2025-10-23 | $70.61M derived: sum of 2 quarters · filed 2025-10-23 | $104.68M 10-Q · filed 2025-10-23 | $133.97M derived: sum of 4 quarters · filed 2026-02-11 | ||||
| 2024-06-30 | $34.05M 10-Q · filed 2025-07-23 | $68.13M 10-Q · filed 2025-07-23 | $97.41M derived: sum of 3 quarters · filed 2026-02-11 | $124.68M derived: sum of 4 quarters · filed 2026-02-11 | ||||
| 2024-03-31 | $34.07M 10-Q · filed 2025-04-24 | $63.36M derived: sum of 2 quarters · filed 2026-02-11 | $90.62M derived: sum of 3 quarters · filed 2026-02-11 | $114.36M derived: sum of 4 quarters · filed 2026-02-11 | ||||
| 2023-12-31 | $29.29M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $56.55M derived: sum of 2 quarters · filed 2026-02-11 | $80.29M derived: sum of 3 quarters · filed 2026-02-11 | $100.83M 10-K · filed 2026-02-11 | ||||
| 2023-09-30 | $27.27M 10-Q · filed 2024-10-23 | $51.01M derived: sum of 2 quarters · filed 2024-10-23 | $71.54M 10-Q · filed 2024-10-23 | $91.83M derived: sum of 4 quarters · filed 2025-02-26 | ||||
| 2023-06-30 | $23.74M 10-Q · filed 2024-07-24 | $44.28M 10-Q · filed 2024-07-24 | $64.56M derived: sum of 3 quarters · filed 2025-02-26 | $80.76M derived: sum of 4 quarters · filed 2025-02-26 | ||||
| 2023-03-31 | $20.54M 10-Q · filed 2024-04-25 | $40.82M derived: sum of 2 quarters · filed 2025-02-26 | $57.02M derived: sum of 3 quarters · filed 2025-02-26 | $74.65M derived: sum of 4 quarters · filed 2025-02-26 | ||||
| 2022-12-31 | $20.28M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $36.48M derived: sum of 2 quarters · filed 2025-02-26 | $54.11M derived: sum of 3 quarters · filed 2025-02-26 | $70.36M 10-K · filed 2025-02-26 | ||||
| 2022-09-30 | $16.20M 10-Q · filed 2023-10-25 | $33.83M derived: sum of 2 quarters · filed 2023-10-25 | $50.07M 10-Q · filed 2023-10-25 | $62.58M derived: sum of 4 quarters · filed 2024-02-07 | ||||
| 2022-06-30 | $17.63M 10-Q · filed 2023-07-26 | $33.88M 10-Q · filed 2023-07-26 | $46.39M derived: sum of 3 quarters · filed 2024-02-07 | $59.79M derived: sum of 4 quarters · filed 2024-02-07 | ||||
| 2022-03-31 | $16.25M 10-Q · filed 2023-04-26 | $28.75M derived: sum of 2 quarters · filed 2024-02-07 | $42.16M derived: sum of 3 quarters · filed 2024-02-07 | $57.70M derived: sum of 4 quarters · filed 2024-02-07 | ||||
| 2021-12-31 | $12.51M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-07 | $25.91M derived: sum of 2 quarters · filed 2024-02-07 | $41.45M derived: sum of 3 quarters · filed 2024-02-07 | $55.68M 10-K · filed 2024-02-07 | ||||
| 2021-09-30 | $13.40M 10-Q · filed 2022-10-26 | $28.94M derived: sum of 2 quarters · filed 2022-10-26 | $43.17M 10-Q · filed 2022-10-26 | $54.44M derived: sum of 4 quarters · filed 2022-10-26 | ||||
| 2021-06-30 | $15.54M 10-Q · filed 2022-07-27 | $29.77M 10-Q · filed 2022-07-27 | $41.03M derived: sum of 3 quarters · filed 2022-07-27 | $50.88M derived: sum of 4 quarters · filed 2022-07-27 | ||||
| 2021-03-31 | $14.23M 10-Q · filed 2022-04-27 | $25.49M derived: sum of 2 quarters · filed 2022-04-27 | $35.34M derived: sum of 3 quarters · filed 2022-04-27 | $45.94M derived: sum of 4 quarters · filed 2022-04-27 | ||||
| 2020-12-31 | $11.27M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-09 | $21.11M derived: sum of 2 quarters · filed 2022-02-09 | $31.71M derived: sum of 3 quarters · filed 2022-02-09 | $42.66M 10-K · filed 2022-02-09 | ||||
| 2020-09-30 | $9.84M 10-Q · filed 2021-11-03 | $20.45M derived: sum of 2 quarters · filed 2021-11-03 | $31.40M 10-Q · filed 2021-11-03 | $40.27M derived: sum of 4 quarters · filed 2021-11-03 | ||||
| 2020-06-30 | $10.61M 10-Q · filed 2021-07-28 | $21.55M 10-Q · filed 2021-07-28 | $30.43M derived: sum of 3 quarters · filed 2021-07-28 | $37.87M derived: sum of 4 quarters · filed 2021-07-28 | ||||
| 2020-03-31 | $10.95M 10-Q · filed 2021-04-28 | $19.82M derived: sum of 2 quarters · filed 2021-04-28 | $27.26M derived: sum of 3 quarters · filed 2021-04-28 | $36.83M derived: sum of 4 quarters · filed 2021-04-28 | ||||
| 2019-12-31 | $8.87M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-17 | $16.31M derived: sum of 2 quarters · filed 2021-02-17 | $25.88M derived: sum of 3 quarters · filed 2021-02-17 | $32.69M 10-K · filed 2021-02-17 | ||||
| 2019-09-30 | $7.44M 10-Q · filed 2020-10-28 | $17.01M derived: sum of 2 quarters · filed 2020-10-28 | $23.81M 10-Q · filed 2020-10-28 | $30.85M derived: sum of 4 quarters · filed 2020-10-28 | ||||
| 2019-06-30 | $9.57M 10-Q · filed 2020-07-29 | $16.38M 10-Q · filed 2020-07-29 | $23.41M derived: sum of 3 quarters · filed 2020-07-29 | $30.81M derived: sum of 4 quarters · filed 2020-07-29 | ||||
| 2019-03-31 | $6.81M 10-Q · filed 2020-04-30 | $13.84M derived: sum of 2 quarters · filed 2020-04-30 | $21.24M derived: sum of 3 quarters · filed 2020-04-30 | $28.16M derived: sum of 4 quarters · filed 2020-04-30 | ||||
| 2018-12-31 | $7.04M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-26 | $14.43M derived: sum of 2 quarters · filed 2020-02-26 | $21.36M derived: sum of 3 quarters · filed 2020-02-26 | $26.16M 10-K · filed 2020-02-26 | ||||
| 2018-09-30 | $7.39M 10-Q · filed 2019-11-05 | $14.32M derived: sum of 2 quarters · filed 2019-11-05 | $19.12M 10-Q · filed 2019-11-05 | $23.55M derived: sum of 4 quarters · filed 2019-11-05 | ||||
| 2018-06-30 | $6.92M 10-Q · filed 2019-08-01 | $11.73M 10-Q · filed 2019-08-01 | $16.16M derived: sum of 3 quarters · filed 2019-08-01 | $20.85M derived: sum of 4 quarters · filed 2019-08-01 | ||||
| 2018-03-31 | $4.80M 10-Q · filed 2019-05-02 | $9.23M derived: sum of 2 quarters · filed 2019-05-02 | $13.92M derived: sum of 3 quarters · filed 2019-05-02 | $18.91M derived: sum of 4 quarters · filed 2019-05-02 | ||||
| 2017-12-31 | $4.43M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-13 | $9.12M derived: sum of 2 quarters · filed 2019-03-13 | $14.10M derived: sum of 3 quarters · filed 2019-03-13 | $19.07M 10-K · filed 2019-03-13 | $19.07M 10-K · filed 2018-03-07 | |||
| 2017-09-30 | $4.69M 10-Q · filed 2018-11-07 | $4.69M 10-Q · filed 2017-11-08 | $9.68M derived: sum of 2 quarters · filed 2018-11-07 | $14.64M 10-Q · filed 2018-11-07 | $14.64M 10-Q · filed 2017-11-08 | $18.38M derived: sum of 4 quarters · filed 2018-11-07 | ||
| 2017-06-30 | $4.98M 10-Q · filed 2018-08-09 | $4.98M 10-Q · filed 2017-08-09 | $9.95M 10-Q · filed 2018-08-09 | $9.95M 10-Q · filed 2017-08-09 | $13.69M derived: sum of 3 quarters · filed 2018-08-09 | $16.95M derived: sum of 4 quarters · filed 2018-08-09 | ||
| 2017-03-31 | $4.97M 10-Q · filed 2018-05-09 | $4.97M 10-Q · filed 2017-05-10 | $8.71M derived: sum of 2 quarters · filed 2018-05-09 | $11.97M derived: sum of 3 quarters · filed 2018-05-09 | $15.55M derived: sum of 4 quarters · filed 2018-05-09 | |||
| 2016-12-31 | $3.74M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-07 | $7.00M derived: sum of 2 quarters · filed 2018-03-07 | $10.58M derived: sum of 3 quarters · filed 2018-03-07 | $13.85M 10-K · filed 2018-03-07 | ||||
| 2016-09-30 | $3.26M 10-Q · filed 2017-11-08 | $6.84M derived: sum of 2 quarters · filed 2017-11-08 | $10.11M 10-Q · filed 2017-11-08 | $14.73M derived: sum of 4 quarters · filed 2017-11-08 | ||||
| 2016-06-30 | $3.58M 10-Q · filed 2017-08-09 | $6.85M 10-Q · filed 2017-08-09 | $11.47M derived: sum of 3 quarters · filed 2017-08-09 | $15.75M derived: sum of 4 quarters · filed 2017-08-09 | ||||
| 2016-03-31 | $3.27M 10-Q · filed 2017-05-10 | $7.89M derived: sum of 2 quarters · filed 2017-05-10 | $12.18M derived: sum of 3 quarters · filed 2017-05-10 | $14.80M derived: sum of 4 quarters · filed 2017-05-10 | ||||
| 2015-12-31 | $4.62M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-21 | $8.91M derived: sum of 2 quarters · filed 2017-03-21 | $11.54M derived: sum of 3 quarters · filed 2017-03-21 | $12.00M 10-K · filed 2017-03-21 | ||||
| 2015-09-30 | $4.29M 10-Q · filed 2016-11-10 | $6.92M derived: sum of 2 quarters · filed 2016-11-10 | $7.38M 10-Q · filed 2016-11-10 | $7.73M derived: sum of 4 quarters · filed 2016-11-10 | ||||
| 2015-06-30 | $2.63M 10-Q · filed 2016-08-11 | $3.09M 10-Q · filed 2016-08-11 | $3.44M derived: sum of 3 quarters · filed 2016-08-11 | $4.59M derived: sum of 4 quarters · filed 2016-08-11 | ||||
| 2015-03-31 | $461.04K 10-Q · filed 2016-05-10 | $814.61K derived: sum of 2 quarters · filed 2016-05-10 | $1.96M derived: sum of 3 quarters · filed 2016-05-10 | $23.72M derived: sum of 4 quarters · filed 2016-05-10 | ||||
| 2014-12-31 | $353.56K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-08 | $1.50M derived: sum of 2 quarters · filed 2016-03-08 | $23.26M derived: sum of 3 quarters · filed 2016-03-08 | $23.47M 10-K · filed 2016-03-08 | ||||
| 2014-09-30 | $1.15M 10-Q · filed 2015-11-05 | $22.90M derived: sum of 2 quarters · filed 2015-11-05 | $23.11M 10-Q · filed 2015-11-05 | |||||
| 2014-06-30 | $21.76M 10-Q · filed 2015-08-14 | $21.97M 10-Q · filed 2015-08-14 | ||||||
| 2014-03-31 | $209.74K 10-Q · filed 2015-06-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |